Hologic and Stryker gear up for earnings with diagnostic wins, surgical growth and strategic moves shaping the medical device ...

If you are wondering whether Stryker’s share price still makes sense at current levels, the key question is how its current ...

Boston Scientific has agreed to acquire Penumbra in a deal worth around $14.5bn, a move that will expand the medtech giant’s ...

Debt Management: Stryker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.76, the ...

Penumbra is expected to give Boston Scientific more of a presence in the vascular surgery market, with little overlap between ...

Explore SPYV: a large-cap value S&P 500 ETF with diversified sectors, a 16% P/E discount, and lower volatility. Read the full ...

The growth of the neurovascular devices market is largely fueled by the increasing burden of neurovascular disorders, rapid technological advancements in devices, a growing preference for minimally ...

The European foot and ankle devices market offers opportunities driven by an aging population, increasing musculoskeletal ...

Boston Scientific agreed to buy medtech firm Penumbra in a $14.5  billion deal on Thursday, its second‑largest takeover ever, ...

With the planned purchase, Boston Scientific will gain several thrombectomy devices to remove clots from blood vessels.

As the curtain falls on the 44th edition of the J.P. Morgan Healthcare Conference in San Francisco, a medtech company CEO ...

Boston Scientific has agreed to acquire Penumbra in a deal worth about $14.5 billion. Boston Scientific has agreed to acquire ...